One trial was performed with 10 mg of the PD-L1 antibody atezolizumab radiolabeled with zirconium-89 (89Zr) and PET imaging on days 4 and 7 in patients with NSCLC, cancer of the urinary tract, and triple negative breast cancer prior to atezolizumab treatment (figure 1) 49. This evidence concerns the gene CD274 and non-small cell lung carcinoma.